Core Insights - Medexus Pharmaceuticals reported a total net revenue of $25.3 million in fiscal Q3 2026, down from $30.0 million year-over-year, with adjusted EBITDA declining to $4.5 million [5][14][16] - The company highlighted the commercial launch of GRAFAPEX, with product-level net revenue of $2.0 million in Q3 2026 and expectations for it to contribute positively to operating cash flow starting in fiscal Q4 2026 [1][3][6] - Management indicated strong demand trends for GRAFAPEX following a holiday slowdown, with January 2026 showing one of the strongest months of patient demand since launch [2][3][6] Financial Performance - Total net revenue for Q3 2026 was $25.3 million, a decrease from $30.0 million in the same quarter last year, attributed to reduced sales of Rupall and the return of Gleolan [5][14][16] - Gross profit was reported at $13.6 million, with a gross margin improvement to 53.6% from 50.7% year-over-year [15] - Operating cash flow for Q3 2026 was $7.8 million, an increase from $6.7 million in the prior year [19] GRAFAPEX Launch and Demand - GRAFAPEX product-level revenue for the nine-month period ended December 31, 2025, was $8.2 million, compared to $8.5 million invested in launch-related personnel and infrastructure [1][6] - Management expects GRAFAPEX to generate product-level net revenue of $11 million to $12 million for fiscal year 2026 [1][6] - As of the report, 32% of 180 U.S. transplant centers had ordered GRAFAPEX, with 77% of those reordering, indicating strong adoption [4][7] Reimbursement and Adoption Dynamics - Reimbursement for GRAFAPEX is characterized as "excellent," with Medicare NTAP potentially covering up to approximately $21,000 for about 30% of adult patients [4][11] - Management noted that transplant activity is concentrated among a subset of centers, with the top 76 centers performing about 80% of transplants, where GRAFAPEX penetration is stronger [8][11] Cash Flow and Debt Management - Cash on hand was reported at $15.0 million as of December 31, 2025, down from $24.0 million at March 31, 2025, while net debt decreased to $10.4 million [20][21] - The company entered a new senior secured credit agreement, reducing quarterly principal repayments to $0.5 million from $3.3 million under the previous facility [21][22] Portfolio Updates - Management provided updates on other products, noting a 17% increase in patient unit demand for Rasuvo due to competitive changes, while Rupall continues to face generic competition [18]

Core Insights - Medexus Pharmaceuticals reported fiscal Q1 2026 results, highlighting a net revenue of $24.6 million and a net income of $0.5 million, with a focus on the successful launch of GRAFAPEX [1][2][8] Financial Performance - Fiscal Q1 2026 net revenue was $24.6 million, a decrease of $2.7 million or 9.9% compared to $27.3 million in fiscal Q1 2025, primarily due to reduced sales of Rupall and Gleolan [9] - Adjusted EBITDA for fiscal Q1 2026 was $3.4 million, down $2.7 million or 44.3% from $6.1 million in fiscal Q1 2025 [9] - Operating income decreased to $0.9 million, a drop of $3.1 million or 77.5% compared to $4.0 million in fiscal Q1 2025 [9] - Available liquidity as of June 30, 2025, was $9.3 million, down from $24.0 million as of March 31, 2025, mainly due to a $15.5 million payment under a credit agreement [9] GRAFAPEX Performance - GRAFAPEX generated $3.0 million in product-level net revenue during fiscal Q1 2026, matching the investment in personnel and infrastructure for the product [3][12] - The company anticipates GRAFAPEX's product-level net revenue for fiscal Q2 2026 to be between $3.0 million and $3.5 million, considering observed wholesaler purchasing patterns [5][12] - GRAFAPEX is expected to contribute positively to quarterly operating cash flows by fiscal Q3 2026 [5][12] Market Response and Future Outlook - Positive market response to GRAFAPEX includes formulary inclusion by nine large commercial payers covering approximately 48 million patient lives [5] - The US Centers for Medicare & Medicaid Services approved New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX, which will provide additional reimbursement starting October 1, 2025 [11] - The company expects annual product-level net revenue from GRAFAPEX to exceed $100 million within five years post-launch [11] Product Portfolio and Competitive Landscape - The company is facing challenges with Rupall, which has seen a 29% decrease in unit demand due to the expiration of market exclusivity and increased generic competition [17] - Other products like Trecondyv and IXINITY have shown varying performance, with Trecondyv experiencing a 38% growth in unit demand over the past year [13][14]